Compare Abeona Therapeutics Inc (ABEO) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $424.33M), while C.H. Robinson Worldwide, Inc. trades at $144.86 (market cap $17.33B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 40.8× Abeona Therapeutics Inc's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.7% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CHRW | |
|---|---|---|
Market Cap | $424.33M | $17.33B |
Sector | Health | Industrials |
52-Week High | $7.45 | $209.42 |
52-Week Low | $4.17 | $118.77 |
Enterprise Value | $279.23M | $19.15B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
